抗血小板治疗降低烟雾病卒中风险的效果:对比增强MR血管壁成像的作用
研究纳入1262例烟雾病患者,按是否接受抗血小板治疗(APT)分组,评估对比增强MR血管壁成像上血管壁强化在APT降低卒中风险中的作用。平均随访37.9个月,未接受APT者脑血管事件发生率略高于接受APT者(12.9% vs 9.7%,HR p=0.069)。亚组分析显示血管壁强化与APT疗效存在显著交互作用,在伴血管壁强化的患者中APT可显著降低卒中风险(HR=0.43,95%CI 0.23-0.79,交互p=0.038)。
要点
- 对比增强MR血管壁成像显示血管壁强化的烟雾病患者,接受APT后卒中风险显著降低(HR=0.43,95%CI 0.23-0.79)。
- 血管壁强化与APT降低卒中风险之间存在显著交互作用(交互p=0.038),提示血管壁强化状态影响APT疗效。
- 总体人群中未接受APT者脑血管事件发生率12.9% vs 接受APT者9.7%,差异未达统计学显著(HR p=0.069)。
核心结论
- APT可能显著降低伴有血管壁强化的烟雾病患者的卒中风险。
研究设计与样本
- 连续纳入的烟雾病患者接受对比增强MR血管壁成像,按是否处方抗血小板药物分为APT组和非APT组,共1262例(平均年龄42.6±11.1岁)纳入最终分析,采用Kaplan-Meier生存分析和Cox回归分析评估APT与卒中风险的关联,并行亚组分析探讨血管壁强化的作用。
关键影像表现/征象
- 对比增强MR血管壁成像用于评估烟雾病患者的血管壁强化。
- 伴血管壁强化的烟雾病患者接受APT后卒中风险显著降低(HR=0.43;95%CI:0.23-0.79)。
诊断标准与关键数值
- 血管壁强化定义为对比增强MR血管壁成像上的血管壁强化表现,其与APT的交互作用p=0.038。
- 伴血管壁强化患者中APT降低卒中风险的HR=0.43(95%CI:0.23-0.79)。
- 总体人群中未接受APT者脑血管事件发生率12.9% vs 接受APT者9.7%,HR p=0.069。
临床应用与阅片要点
- 对比增强高分辨率MRI可能有助于识别最可能从APT获益的烟雾病患者。
- 作者在要点中提出,伴血管壁强化的烟雾病患者应强烈推荐APT。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate the role of vessel wall enhancement in the efficacy of antiplatelet therapy (APT) on reducing the stroke risk in patients with Moyamoya disease (MMD) based on postcontrast MR vessel wall imaging.
METHODS: Consecutive patients with MMD underwent postcontrast MR vessel wall imaging and were divided into APT and non-APT groups according to the prescribed antiplatelet agents. Kaplan-Meier survival and Cox regression analyses were performed to determine the association between APT and stroke risk of patients with MMD, and subgroup analysis was performed to determine the role of vessel wall enhancement in reducing stroke risk after APT.
RESULTS: A total of 1262 patients (mean age: 42.6 ± 11.1 years) were finally included for analysis. Compared with patients without APT, those with APT were older (p = 0.023) and had a higher incidence of hypertension (p = 0.015), and with advanced Suzuki stage (≥ IV) (p < 0.001). During an average follow-up of 37.9 months, patients without APT had a marginally greater incidence of cerebrovascular events (12.9% vs. 9.7%; HR p = 0.069) than those who underwent APT before and after propensity score matching. The subgroup analyses revealed that vessel wall enhancement had a significant interaction effect on the association between APT and stroke outcomes, and APT could significantly reduce stroke risk in MMD patients with vessel wall enhancement (HR = 0.43; 95% CI: 0.23-0.79, interaction p = 0.038).
CONCLUSION: APT may significantly reduce stroke risk in patients with MMD with vessel wall enhancement.
KEY POINTS: Question The effect of antiplatelet therapy (APT) varies in patients with moyamoya disease (MMD). Findings APT may significantly reduce stroke risk for MMD patients with vessel wall enhancement. Clinical relevance Post-contrast high-resolution MRI may help identify MMD patients who would mostly benefit from APT; APT should be highly recommended in MMD patients with vessel wall enhancement.
引用
- Lu M, Zhang H, Liu S, et al. Effects of antiplatelet therapy on reducing stroke risk in patients with moyamoya disease: the role of postcontrast MR vessel wall imaging. Eur Radiol. 2025. PMID: 40214736. doi:10.1007/s00330-025-11562-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。